drugset / Trial / NCT01902758
Drug Combination on Exercise Performance at High Altitude
Non-randomizedParallel-groupTriple-blind
Summary
This study is being conducted to determine the effectiveness of using two FDA approved medications in concert to reduce the likelihood of sickness due to low oxygen levels and to reduce the decrement in physical performance at higher elevations. The investigators hypothesize that this drug combination will reduce the symptoms of acute mountain sickness and improve exercise performance at high altitude compared to placebo.
Timeline
- Start
- 2013-08
- Primary completion
- 2013-08
- Completion
- 2013-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ambrisentan | Small molecule | 5 mg | — |
| Subject | Theophylline | Small molecule | 400 mg | — |